OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

1 Projects | 1 Researchers | $245,313 Invested

2023

Ultimate Medicine

Antal Szalay, MD, MBA

Development of a non-invasive biomarker for early detection of Alzheimer’s disease and patient stratification based on the delta-valerobetaine pathway.

  • Funding Amount: $245,313
  • Organization Type: Biotechnology/For Profit
  • Program: Diagnostics Accelerator
  • Target: Mitochondria/Metabolic Function
  • Status: Closed